Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

Ministers target obesity, mental health and skills gap in sweeping reforms to tackle economic inactivity and unemployment ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...